ReviewBlood2017
Heparin-induced thrombocytopenia.
Review in Blood, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06163144 (Risk Factors of Thrombocytopenia In Chronic Kidney Disease And Hemodialysis Patients In Assiut University Hospitals), which is not on this map. Cited by 216 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Risk Factors of Thrombocytopenia In Chronic Kidney Disease And Hemodialysis Patients In Assiut University Hospitals
Who cites it
216 citing papers in PubMed, 3 syntheses or guidelines pooled it, 413 citations in OpenAlex.
- Thromboembolism after COVID-19 Vaccination: A Systematic Review of Such Events in 286 Patients.Annals of vascular surgery · 2022Pooled it
- Cardiovascular and haematological events post COVID-19 vaccination: A systematic review.Journal of cellular and molecular medicine · 2022Pooled it
- ISTH DIC subcommittee communication on anticoagulation in COVID-19.Journal of thrombosis and haemostasis : JTH · 2020Guideline
- Evaluation of heparin gel's effects on stage II pressure ulcers: a randomized controlled trial.European journal of medical research · 2025Trial
- Skin graft surgery and its impact on platelet counts in Iranian burn patients: a non-randomized clinical trial.BMC surgery · 2024Trial
- Electrospun Heparin-Loaded PCL Nanofiber Sutures with Sustained Release for Antithrombotic Applications.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Robust and durable zwitterionic hydrogel coating with catechol-CuBioactive materials · 2026Article
- Drugs to Prevent and Treat Venous Thromboembolic Disease During Pregnancy.Clinics in perinatology · 2026Review
- Massive aortic thrombus in a hypercoagulable patient with heparin induced thrombocytopenia: a case report.Journal of surgical case reports · 2026Article
- Platelet homeostasis and heterogeneity in inflammation and sepsis: mechanisms, biological effects, and clinical potential.Cell communication and signaling : CCS · 2026Review
- Non-PF4/heparin-binding, platelet-activating antibodies in heparin-induced thrombocytopenia.Blood · 2026Article
- Predominance of autoimmune heparin-induced thrombocytopenia in a nephrology department.Research and practice in thrombosis and haemostasis · 2026Article
- Ticagrelor-Induced False-Negative Serotonin Release Assay in Heparin-Induced Thrombocytopenia With Stent Thrombosis.JACC. Case reports · 2026Article
- Atypical memory B cell clonal expansion and inflammatory programs associate with platelet-activating antibody development in COVID-19.JCI insight · 2026Article
- Off-Pump Coronary Artery Bypass Grafting With Nafamostat in a Patient With Kasabach-Merritt Syndrome: A Case Report.Cureus · 2026Article
- Pharmacological Management of Thrombosis: Current State and Future Strategies.International journal of molecular sciences · 2026Review
- Translational immunothrombosis in autoimmune Heparin-Induced thrombocytopenia: targeting the FcγRIIa-Syk-BTK and complement pathways.Clinical and experimental medicine · 2026Review
- Concomitant pulmonary embolism and severe thrombocytopenia associated with an APS-like autoimmune thrombophilic condition: a case report.BMC pulmonary medicine · 2026Article
- Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT)-like Syndrome: A Case Report and Some Considerations on a Novel Diagnostic and Therapeutic Challenge.Diagnostics (Basel, Switzerland) · 2026Article
- Ultra-Low Dose Argatroban in Heparin-Induced Thrombocytopenia with Thrombocytopenia and Hypofibrinogenemia: A Case Report.TH open : companion journal to thrombosis and haemostasis · 2026Article
156 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Heparin-induced thrombocytopenia (HIT) is an immune complication of heparin therapy caused by antibodies to complexes of platelet factor 4 (PF4) and heparin. Pathogenic antibodies to PF4/heparin bind and activate cellular FcγRIIA on platelets and monocytes to propagate a hypercoagulable state culminating in life-threatening thrombosis. It is now recognized that anti-PF4/heparin antibodies develop commonly after heparin exposure, but only a subset of sensitized patients progress to life-threatening complications of thrombocytopenia and thrombosis. Recent scientific developments have clarified mechanisms underlying PF4/heparin immunogenicity, disease susceptibility, and clinical manifestations of disease. Insights from clinical and laboratory findings have also been recently harnessed for disease prevention. This review will summarize our current understanding of HIT by reviewing pathogenesis, essential clinical and laboratory features, and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.